Viatris (VTRS) Cash from Investing Activities (2019 - 2026)
Viatris' (VTRS) quarterly Cash from Investing Activities came in at $277.4 million in Q1 2026, up 526.11% year-on-year from $44.3 million in Q1 2025, and up 231.34% quarter-over-quarter from -$211.2 million in Q4 2025.
Viatris (VTRS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Viatris' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $277.4 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 526.11% year-over-year to $277.4 million in Q1 2026; TTM through Mar 2026 was -$85.2 million, a 104.51% decrease from a year earlier, with the FY2025 full-year figure at -$427.7 million, down 123.75% from the prior year.
- Cash from Investing Activities improved to $277.4 million in Q1 2026 per VTRS's latest filing, from -$211.2 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.7 billion in Q3 2024 and bottomed at -$749.5 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$66.9 million (2022), against an average of $132.9 million.
- Across the five-year window, Cash from Investing Activities sank 1020.33% in 2023 and surged 3283.79% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $1.7 billion in 2022, then tumbled by 98.46% to $26.7 million in 2023, then sank by 731.84% to -$168.7 million in 2024, then fell by 25.19% to -$211.2 million in 2025, then surged by 231.34% to $277.4 million in 2026.
- Per Business Quant, the three latest VTRS Cash from Investing Activities figures stand at $277.4 million (Q1 2026), -$211.2 million (Q4 2025), and -$98.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.13 Bn | 20.97 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 277.40 Mn |
| Mar 31, 2026 | 277.40 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Dec 31, 2025 | -211.20 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Sep 30, 2025 | -98.90 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Jun 30, 2025 | -52.50 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Mar 31, 2025 | -65.10 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Dec 31, 2024 | -168.70 Mn |
| Sep 30, 2024 | 1.75 Bn |
| Sep 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 375.80 Mn |
| Jun 30, 2024 | 375.80 Mn |
| Mar 31, 2024 | -154.30 Mn |
| Mar 31, 2024 | -154.30 Mn |
| Dec 31, 2023 | 26.70 Mn |
| Dec 31, 2023 | 26.70 Mn |